J Pharm Pharmacogn Res 3(suppl. 1): S31, 2015
Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015 September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.
OC-13: CLINICAL TRIALS USING NATURAL PRODUCTS DEVELOPED BY THE CENTER FOR PHARMACEUTICAL RESEARCH AND DRUG DEVELOPMENT. CURRENT STATUS AND PERSPECTIVES
García-García I, Jiménez-Rodríguez D, Festary-Casanovas T, Delgado-Hernández R.
Products obtained from medicinal plants with healing properties could be used to improve medical attendance. Nevertheless, their application in some diseases is not always supported by evidence-based medicine criteria. Similar to chemical and biotech products, natural compounds have to be evaluated in the clinics through randomized, controlled clinical trials that clearly demonstrate their efficacy and safety in the treated patients. The aim of this work is to show an overview of the clinical development of natural products obtained by CIDEM, as well as the future prospects in this field. In a placebo-controlled, double-blind trial, Plectranthus amboinicus Lour Spreng (French oregano) tablets were a belter alternative than symptomatic treatment to suppress common cold in patients with upper respiratory diseases. A novel oral formulation containing microencapsulated lipophilic extract of pumpkin seed oil (Calprost) was studied in older patients diagnosed with Benign Prostatic Hyperplasia (BPH). Their general effect was similar to a group of patients treated with terazosin capsules (control group) but urinary symptoms decreased more markedly in the Calprost group, with a better tolerability. Regarding future perspectives, the incorporation of natural products with anti-tumor properties, produced by CIDEM, to the conventional treatment of cancer patients could be specially beneficial in advanced stages of the disease. In that sense, several protocols using the products aloe 50% aqueous extract (viscous solution); calendula 1% cream, Calprost capsules and VIMANGÒ-mangiferin are under preparation. On the other hand, Justicia pectoralis Jacq (Linden) tablets will be used in patients with neurotic disorders related to stress, through a randomized, placebo-controlled trial. Additionally, a nutritional supplement containing Momordica charantia could be a reasonable option as hypoglycemic in patients with type II Diabetes Mellitus. This biological action will be evaluated in a phase II, randomized, placebo-controlled double-blind trial.
Citation Format: García-García I, Jiménez-Rodríguez D, Festary-Casanovas T, Delgado-Hernández R (2015) Clinical trials using natural products developed by the center for pharmaceutical research and drug development. Current status and perspectives. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S31. Abstract nr OC-13.